Actoxumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Clostridioides difficile toxin A |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6476H10000N1740O2010S45 |
| Molar mass | 145836.11 g·mol−1 |
Actoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridioides difficile infection.
This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School. The project was then licensed to Merck & Co., Inc. for further development and commercialization.
A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.